Recently, MMP1 has been implicated as a promoter of angiogenesis and in the context of tumour sensitivity to CRT, neovascularisation, vascularity and hypoxia are all factors that significantly influence tumour response to therapy [40]. The gene discussed is MMP1; the disease is neoplasm.